We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.14% | 34.95 | 34.85 | 35.00 | 35.75 | 34.45 | 35.75 | 330,994 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 205.88 | 189.05M |
TIDMAPH
RNS Number : 2950O
Alliance Pharma PLC
27 May 2015
For immediate release 27 May 2015
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
AGM Statement
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting ("AGM") in London later this morning. At the meeting, the Company's Chairman, Andrew Smith, will make the following statement:
"Trading in the first four months of 2015 has been satisfactory with revenue of GBP15.6 million, which is 6% higher than the same period last year (2014: GBP14.7 million).
"Hydromol(TM), our biggest brand, has continued to grow strongly, with sales in the first four months of the year up 14% on the same period in the prior year. In the first three months after acquisition, MacuShield(TM) sales have been in line with our expectations, up 12% on the same period the previous year.
"We continue to expect supplies of ImmuCyst(TM) to be resumed in the second half of the year, though initial quantities are still uncertain.
"As previously announced, Richard Wright will be stepping down as Finance Director on 31 May 2015. On behalf of the Board, I extend our thanks to Richard for his excellent work at Alliance and wish him every success in the future. The process to recruit his replacement is progressing well.
"We have a strong pipeline of potential acquisition opportunities and have more than GBP20 million of undrawn bank facilities available to us.
"We look forward to the remainder of 2015 with confidence."
For further information:
Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Richard Wright, Finance Director www.alliancepharma.co.uk + 44 (0) 20 7466 Buchanan 5000 Mark Court / Sophie Cowles / Jane Glover + 44 (0) 20 7260 Numis Securities Limited 1000 Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: David Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMPKADPKBKBDPB
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions